AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

AbbVie's immunology and inflammation (I&I) portfolio continues to be a significant growth driver, with Skyrizi and Rinvoq showing robust performance. These two drugs are increasingly important as ...